RxDoctor Payments DataLook up a doctor →

Jose Mandry, MD

Endocrinology, Diabetes & Metabolism · Ocoee, FLNPI 1386674794

Payments from drug & device makers

$9,142,100in general payments, 2019–2025

Across 1,208 payments — averaging $7567.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2.8M
  • AstraZeneca$2M
  • AbbVie$1.7M
  • Boehringer Ingelheim$1.2M
  • Sanofi US Services Inc.$464K
  • CSL Behring$384K
  • plus $593K from 54 others
$62,592in research payments, 2019–2025

Across 22 payments — averaging $2845.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$60K
  • Sanofi-aventis U.S. LLC$1K
  • Sanofi US Services Inc.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly38$2,801,131
AstraZeneca(2 entities)55$2,026,687
AbbVie123$1,660,786
Boehringer Ingelheim72$1,212,862
Sanofi US Services Inc.41$464,188
CSL Behring58$383,572
Kowa Research Institute, Inc.29$167,388
Bayer41$157,354
Amgen(2 entities)44$133,658
Boehringer Ingelheim International GmbH167$62,195
Radius Health, Inc.52$25,365
Eli Lilly Export S.A. Puerto Rico Branch1$14,782
Pfizer4$10,066
Lexicon Pharmaceuticals, Inc.2$8,319
Novo Nordisk65$3,376
Sanofi-aventis U.S. LLC64$1,759
Lilly USA, LLC71$1,607
Dexcom, Inc.26$771
Astrazeneca UK Limited7$639
Esperion Therapeutics, Inc.14$550
Xeris Pharmaceuticals, Inc.27$529
Tandem Diabetes Care, Inc.16$488
Corcept Therapeutics14$368
IBSA Pharma Inc.11$323
Amneal Pharmaceuticals LLC18$314
Clarus Therapeutics Inc.6$302
Johnson & Johnson17$236
Abbott11$228
Mannkind Corporation12$217
Medtronic(2 entities)11$209
Merck13$193
Amarin Pharma, Inc.10$168
Shire North American Group Inc7$147
Nevro Corp.6$132
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$108
Recordati_rare_diseases_inc.5$108
Cequr Corporation1$86
Ascendis Pharma Endocrinology Inc3$85
Novartis2$59
Acerus Pharmaceuticals Corporation4$58
Takeda Pharmaceuticals U.S.A., Inc.2$53
Insulet Corporation3$52
Boston Scientific1$51
BETA Bionics, Inc.2$50
Ascensia Diabetes Care US Inc.2$47
Antares Pharma, Inc.3$44
Amphastar Pharmaceuticals, Inc.2$39
Rhythm Pharmaceuticals, Inc.1$33
Zealand Pharma US, Inc.2$32
Novo Nordisk AS2$28
Neurocrine Biosciences, Inc.1$25
Madrigal Pharmaceuticals1$25
Globus Medical1$25
GRT US Holding, Inc.1$24
Tolmar, Inc.1$22
Amryt Pharma Holdings Ltd1$20
Sequel Med Tech, LLC1$16
Companion Medical, Inc.1$16
GSK1$16
Acella Pharmaceuticals, LLC1$15

How this compares

$9,142,100 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$105,633
Medicare patients
439
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Ocoee

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →